Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. Carbone DP, et al. Among authors: krejci j. N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493. N Engl J Med. 2017. PMID: 28636851 Free PMC article.
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer.
Svaton M, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Jakubikova L, Cernovska M, Hrnciarik M, Jirousek M, Krejci J, Krejci D, Bilek O, Blazek J, Hurdalkova K, Barinova M, Melichar B. Svaton M, et al. Among authors: krejci d, krejci j. Anticancer Res. 2020 Apr;40(4):2209-2217. doi: 10.21873/anticanres.14182. Anticancer Res. 2020. PMID: 32234916
Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry.
Brat K, Bratova M, Skrickova J, Barinova M, Hurdalkova K, Pesek M, Havel L, Koubkova L, Hrnciarik M, Krejci J, Fischer O, Zemanova M, Coupkova H, Svaton M. Brat K, et al. Among authors: krejci j. Thorac Cancer. 2020 Nov;11(11):3346-3356. doi: 10.1111/1759-7714.13679. Epub 2020 Oct 5. Thorac Cancer. 2020. PMID: 33016001 Free PMC article.
Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.
Venclicek O, Skrickova J, Brat K, Fischer O, Havel L, Hrnciarik M, Marel M, Opalka P, Krakorova G, Rozsivalova D, Kultan J, Mullerova A, Zarnayova L, Smickova P, Vasakova M, Gyorfy Z, Jirousek M, Krejci D, Krejci J, Zuna P, Svaton M, Hrda K, Duba J, Alahakoon J, Svoboda M, Silar J. Venclicek O, et al. Among authors: krejci d, krejci j. Anticancer Res. 2021 Nov;41(11):5549-5556. doi: 10.21873/anticanres.15368. Anticancer Res. 2021. PMID: 34732425
Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.
Bratova M, Skrickova J, Matusikova M, Hrabcova K, Havel L, Koubkova L, Hrnciarik M, Krejci J, Fischer O, Svaton M, Brat K. Bratova M, et al. Among authors: krejci j. J Cancer Res Clin Oncol. 2023 Dec;149(19):17123-17131. doi: 10.1007/s00432-023-05431-5. Epub 2023 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 37768380 Free PMC article.
[TARCEVA Clinical Registry].
Skricková J, Pesek M, Zatloukal P, Kolek V, Salajka F, Koubková L, Krejcí J, Tomísková M, Grygárková Y, Havel L, Hrnciarik M, Skalová B, Stícha M. Skricková J, et al. Among authors: krejci j. Klin Onkol. 2010;23(5):361-3. Klin Onkol. 2010. PMID: 21061685 Czech. No abstract available.
312 results